#USA #Ablation Technology #Del Medtech #Steven Mickelsen #Cardiff by the Sea

Introduction to Del Medtech

Dr. Steven Mickelsen, a renowned electrophysiologist and pioneer in pulsed field ablation (PFA), has officially launched Del Medtech Inc. This innovative startup aims to advance minimally invasive ablation technologies beyond traditional cardiac applications. The company is dedicated to addressing unmet medical needs across diverse therapeutic areas, including gastroenterology, ENT (ear, nose, and throat), men’s and women’s health, and oncology.

The Vision Behind Del Medtech

In announcing the launch of Del Medtech, Dr. Mickelsen emphasized the company’s mission. "Our vision is to establish a new global standard in minimally invasive tissue ablation," he stated. He noted the significant impact PFA technologies have had on catheter ablation procedures over the past five years. Drawing on these experiences, Del Medtech seeks to tackle persistent challenges in healthcare that extend beyond cardiac care.

Innovative Single-Use Devices

Del Medtech is currently developing single-use ablation devices specifically engineered to enhance efficiency and patient outcomes. The focus on single-use technology is expected to streamline procedures and reduce the risks associated with reusable devices. The anticipated market for these innovative devices is substantial, with annual revenue projections ranging from $1.4 billion to $7.4 billion and growth rates expected between 9% and 13%.

The Journey Ahead

Standing at the forefront of a rapidly evolving field, Dr. Mickelsen is eager to showcase Del Medtech’s innovations. He will present the company’s vision at the LSI Emerging Medtech Summit in London on September 8. This event brings together global leaders in healthcare innovation to discuss the future of medical technology. Dr. Mickelsen remarked, "We are entering a period of rapid acceleration in ablative therapies, reminiscent of the rise of PFA in electrophysiology. Del Medtech is well-positioned to lead this trend, and we welcome investors and partners to join us in shaping the future of ablation."

Conclusion

Founded in 2024, Del Medtech Inc. stands as a testament to the ongoing evolution of medical devices. With its focus on expanding PFA applications beyond cardiology, the company is well on its way to redefining the landscape of minimally invasive therapies. By inviting partners and investors to collaborate, Del Medtech aims to usher in a transformative era of healthcare technology that prioritizes patient comfort and effective treatment methods.